DigestRedComo funciona
Red
/
Empresas
Co
No verificado

Coya Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

57 Comunicados de prensa

Ver todos los comunicados de prensa
18/06/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
15/06/2026
Web y redes sociales
Ciencia
Deportes
Medicina - Varios
Fútbol
Biotecnología
Salud
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
08/06/2026
Industria
Ciencia
Medicina - Varios
Biología
Biotecnología
Sanidad
Salud
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
27/05/2026
Biotecnología
Sanidad
Salud
Farmacéutica
Eventos
Industria
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
12/05/2026
Web y redes sociales
Telefonía
Mercado de valores
Biotecnología
Farmacéutica
Sanidad
Salud
Higiene alimentaria
Psiquiatría
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
12/05/2026
Industria
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
09/04/2026
Industria
Biotecnología
Higiene alimentaria
Salud
Sanidad
Farmacéutica
Ciencia
Psiquiatría
Medicina - Varios
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
02/04/2026
Mercado laboral
Sanidad
Ciencia
Farmacéutica
Medicina - Varios
Biotecnología
Higiene alimentaria
Salud
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
18/03/2026
Análisis de Mercados
Industria
Salud
Biotecnología
Sanidad
Ciencia
Farmacéutica
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/03/2026
Psiquiatría
Higiene alimentaria
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Mercado de valores
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0